Strides Pharma Science reported a 16% year-on-year increase in standalone net profit for the quarter ended June 30, 2026, reaching ₹2,113.26 lakh. The pharmaceutical company’s total income from operations rose to ₹20,870.93 lakh from ₹19,664.02 lakh in the same period last year, demonstrating resilient top-line growth amid market fluctuations.

The Board of Directors approved the unaudited financial results on July 31, 2026, following a review by the Audit Committee. The statutory auditors carried out a limited review of the accounts. These results were filed with the National Stock Exchange of India Limited and BSE Limited pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

Standalone profit before tax increased to ₹2,814.42 lakh from ₹2,386.18 lakh in Q1FY25. Consolidated net profit stood at ₹2,090.90 lakh, compared to ₹2,049.05 lakh in the corresponding quarter of the previous fiscal year. Earnings per share (basic) were reported at ₹2.26 for the standalone entity and ₹2.23 for the consolidated entity.

What the Numbers Show

While revenue growth remained positive year-on-year, there was a sequential decline in total income from operations, which fell from ₹24,052.19 lakh in Q4FY26 to ₹20,870.93 lakh in Q1FY26. This quarter-over-quarter contraction suggests potential seasonality or specific project cycles affecting the top line. However, the net profit margin remained stable, indicating effective cost management despite the lower revenue base compared to the preceding quarter.

Strides Pharma Science reported a consolidated net profit of ₹1.6 billion for Q1FY27, compared to ₹1 billion in the same quarter of the previous year, reflecting a significant year-on-year improvement in bottom-line performance. The results were discussed during the company's earnings conference call held on July 31, 2026, at 5:00 PM IST, where management provided insights into the quarterly financial outcomes and operational developments.

Q1FY27 Financial Highlights

The latest quarterly results underscore a notable improvement in profitability for Strides Pharma Science on a year-on-year basis. The following table summarises the key financial metric reported:

Earnings Conference Call Details

The Q1FY27 results were presented to investors and analysts through a scheduled earnings conference call. The management team led the discussion, offering insights into operational metrics and financial outcomes for the period. Key executives who participated in the call included:

• Badree Komandur, Managing Director & Group CEO
• Vikesh Kumar, Group CFO

The invitation for the call was issued by Manjula Ramamurthy, Company Secretary & Compliance Officer, on July 24, 2026.

Participants joined the session via webcast or through dial-in numbers available for India, the USA, the UK, Singapore, and Hong Kong. Detailed joining instructions and the formal invitation are available on the company's website at www.strides.com .

Investor Significance

This quarterly earnings disclosure is a standard regulatory practice for listed entities in India, ensuring transparency in financial reporting. The year-on-year improvement in consolidated net profit provides stakeholders with a direct measure of the company's financial progress, with management available to address queries on revenue drivers, margin trends, and other material developments from the Q1FY27 period.